GSK, Teva Fight FTC Bid To Join Lamictal Args In 3rd Circ.
GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. on Friday urged the Third Circuit to reject the Federal Trade Commission's request to participate in oral arguments in the Lamictal pay-for-delay litigation, saying...To view the full article, register now.
Already a subscriber? Click here to view full article